- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03858439
Dietary Intervention in ADPKD on Tolvaptan (DIAT)
Dietary Intervention in Patients With ADPKD on Tolvaptan: Urine Output and Quality of Life
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited renal disorder affecting 12.5 million persons worldwide, and impacting approximately 35,000-66,000 Canadians. An estimated 45% to 70% of patients with ADPKD progress to end-stage renal disease by age 65 years.
Tolvaptan has been approved in Canada as a treatment for ADPKD. Tolvaptan was discovered in Japan by Otsuka Pharmaceutical and was first approved there for ADPKD in 2014. The Health Canada approval of Tolvaptan is based on the results of the pivotal Phase 3 randomized, double-blind and placebo-controlled TEMPO 3:4 Trial, the largest study conducted to date in adults with ADPKD.
The treatment of ADPKD had previously been symptomatic with the aim of reducing morbidity and mortality associated with disease manifestations. This changed with the publication of the TEMPO 3:4 trial, which proved the efficacy of the arginine vasopressin (AVP) V2 receptor antagonist tolvaptan in decreasing the progression of CKD. In this trial, 1445 patients with ADPKD eGFR > 60 were randomized to receive either placebo or tolvaptan in a split-dose regimen of 45 mg in the morning and 15 mg in the afternoon, up titrated to 90/30 mg as tolerated. The REPRISE study investigated the value of tolvaptan in 1300 patients with lower levels of eGFR (25-65 mL/min/1.73 m2).
AVP plays a major role in the pathogenesis of cysts in ADPKD via cAMP stimulation. The AVP antagonist blocks V2 receptors in collecting ducts and therefore blocks the concentrating ability of the tubule. This leads to increased urine volume. Recently, it has been demonstrated that this increased urine volume is related to solute excretion. Therefore, it seems possible that dietary modification to decrease solute intake (salt, protein) would decrease the urine volume in patients taking tolvaptan.
The most common side effect of AVP antagonist is increased renal water excretion which presents as polyuria, nocturia, increased thirst, and dry mouth. The daily urine volumes 5 days after starting different split doses of tolvaptan (15/15, 30/0, 30/15, 30/30 mg) in a preliminary phase 2 study were 4 to 6 L. In the treatment of hyponatremia and heart failure (another indication for tolvaptan therapy), a meta-analysis found an average increase in water clearance of only 68 mL/h after tolvaptan treatment. This more modest increase in urine output may be related to the low sodium diet most of these patients should be adhering to.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Peter Margetts, MD PhD
- Phone Number: 32299 9055221155
- Email: margetts@mcmaster.ca
Study Locations
-
-
Ontario
-
Hamilton, Ontario, Canada, L8N 4A6
- St. Joseph's Healthcare
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients seen in the Hamilton Nephrology Genetics Clinic with a diagnosis of ADPKD taking tolvaptan
- Able to provide informed consent
- On maximal tolerated dose of tolvaptan for at least 3 months
Exclusion Criteria:
- Serum sodium > 135 mmol/L
- Patients with evidence of non-compliance (not completing monthly blood work required while on tolvaptan therapy).
- Unlikely to continue in Hamilton Nephrology Genetics Clinic for at least 6 months (planned dialysis initiation, transplant)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention
Single arm study.
All participants will receive dietary intervention.
|
Low sodium, low protein dietary recommendation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in 24-hour urine volume
Time Frame: Change from baseline to 3 months
|
24-hour urine volume in ml.
|
Change from baseline to 3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in ADPKD-IS
Time Frame: Change from baseline to 3 months
|
Autosomal dominant polycystic kidney disease impact score - quality of life.
Eighteen items, score from 18 to 90 with higher values reflecting lower quality of life
|
Change from baseline to 3 months
|
Change in Nagasaki Diabetes Insipidus Questionnaire
Time Frame: Change from baseline to 3 months
|
Validated measure of polyuria on quality of life.
Subset of questions 1-10 will be used (Questions 11-12 relate to therapy with DDAVP).
Score from 10 to 40 with higher scores reflecting worse quality of life.
|
Change from baseline to 3 months
|
Change in urine total solute
Time Frame: Change from baseline to 3 months
|
Urine total solute measured by (urine sodium + urine urea) * urine volume
|
Change from baseline to 3 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Kidney Diseases
- Urologic Diseases
- Urological Manifestations
- Congenital Abnormalities
- Genetic Diseases, Inborn
- Urination Disorders
- Abnormalities, Multiple
- Kidney Diseases, Cystic
- Ciliopathies
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Polycystic Kidney Diseases
- Polycystic Kidney, Autosomal Dominant
- Polyuria
Other Study ID Numbers
- v1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Polyuria
-
University Hospital, GhentCompletedNocturnal PolyuriaBelgium
-
University Hospital, GhentCompleted
-
Sanwa Kagaku Kenkyusho Co., Ltd.CompletedNocturia Due to Nocturnal PolyuriaJapan
-
Ferring PharmaceuticalsCompleted
-
Ferring PharmaceuticalsCompletedNocturia Associated With Nocturnal PolyuriaGermany
-
Universitaire Ziekenhuizen KU LeuvenRecruitingNocturia | Urogenital Cancer | Lower Limb Lymphedema | Nocturnal PolyuriaBelgium
-
University Hospital, Basel, SwitzerlandCompletedHealthy | Polyuria-polydipsia SyndromeSwitzerland
-
Ferring PharmaceuticalsCompletedNocturia Due to Nocturnal PolyuriaJapan
-
University Hospital, Basel, SwitzerlandCompletedPolyuria-polydipsia SyndromeSwitzerland
-
Potrero MedicalCompleted
Clinical Trials on Dietary
-
University of ViennaCompletedEndotoxemia | Dietary HabitsAustria
-
University Hospital, ToulouseCompleted
-
Center of Food and Fermentation TechnologiesCompleted
-
Heriot-Watt UniversityUniversity of EdinburghCompleted
-
Second Affiliated Hospital, School of Medicine,...Recruiting
-
University of AlbertaCargill; Canada Foundation for Innovation; Nestlé Health Science Spain; Government... and other collaboratorsCompleted
-
Federal University of Rio Grande do SulNot yet recruitingEffects of Time-restricted Eating and Aerobic Exercise Training in Women With Overweight and ObesityObesity | Overweight and Obesity | Time Restricted Feeding | Intermittent Fasting | Time Restricted Eating
-
Vanderbilt UniversityWithdrawn
-
University of California, San FranciscoCompletedStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
University of GaziantepCompletedIrritable Bowel SyndromeTurkey